Why did my insurance stop covering Zepbound in 2026?

Did CVS Caremark drop Zepbound, and is it coming back?

Yes. CVS Caremark removed Zepbound from its Standard, Advanced Control, and Value commercial formularies on July 1, 2025, after negotiating preferred placement for Novo Nordisk's Wegovy, a move NBC News reported affected an estimated 200,000 patients. If your pharmacy benefits run through Caremark, this exclusion is the most likely reason your Zepbound claims started rejecting.

It is reversing. On May 28, 2026, CVS Caremark announced Zepbound will return to its most common commercial formularies as an additional preferred option effective October 1, 2026. Two caveats matter: formulary placement does not guarantee your specific plan covers weight loss medications at all, since employers make that call, and prior authorization requirements will still apply. If you were switched off Zepbound during the exclusion, ask your physician whether it makes sense to revisit the plan after October 1.

Why are employers cutting GLP-1 coverage for weight loss?

Cost is the driver. Per Mercer data reported by CNBC, nearly half of large employers covered GLP-1s for weight loss in 2025, but 6% of employers with 500 or more employees dropped that coverage in 2026 and 5% more are considering it for 2027. In an NFP employer survey, 51% of employers named GLP-1s the single biggest driver of rising prescription drug costs.

Employers also worry about persistence and demand. Many members stop treatment within the first year while the plan has already absorbed months of cost, and the arrival of oral GLP-1s in 2026 is expected to increase demand without lowering per-member prices. Employer surveys reported by CNBC find most companies expect the new pills to increase GLP-1 demand, while few expect prices to fall. Most of these cuts target the weight loss indication specifically; coverage for type 2 diabetes generally remains.

What can I do if my plan dropped Zepbound?

Start by finding out exactly why the claim was denied, because the fix depends on the mechanism. Ask your insurer or HR whether the plan excluded the weight loss benefit entirely, excluded Zepbound specifically in favor of another GLP-1, or simply needs a new prior authorization.

If Zepbound was excluded but another GLP-1 is preferred, your physician can discuss whether switching is reasonable or file a formulary exception with documentation of why the preferred alternative is not appropriate for you. KFF Health News reports that appeals with strong medical evidence do succeed, so keep records of medications tried, test results, and any step therapy already completed. Also check other indications: some plans that deny weight loss coverage still cover tirzepatide products for type 2 diabetes or Zepbound for obstructive sleep apnea when documented. Whether any of these paths fits your situation is a decision for your physician, not the insurer's marketing materials.

What does Zepbound cost without insurance in 2026?

Without coverage, Zepbound's list price is about $1,086 per month, but almost no cash payer needs to pay that. As of December 1, 2025, LillyDirect sells single-dose Zepbound vials to cash-paying patients for $299 per month at the 2.5 mg starting dose, $399 at 5 mg, and $449 for all higher doses. These self-pay prices cannot be combined with insurance, and vials require drawing up the dose with a syringe rather than using a pen. Medication prices at these channels typically exclude the prescriber visit, so budget for the consultation separately.

Telehealth memberships are another route to physician-supervised weight loss care. Sipra's membership is $99/mo with medication from $79/mo, $178/mo all-in at the lowest tier, and you are not charged until a physician approves treatment. Full cost disclosed before checkout. Availability varies by state; telehealth prescribing rules, pharmacy options, and specific medications differ depending on where you live. To compare what different providers actually charge all-in, the provider cost calculator at /calculators/provider-cost lines the options up side by side.

Does Medicare cover Zepbound in 2026?

Starting July 1, 2026, some Medicare enrollees can get Zepbound for a $50 monthly copay through the Medicare GLP-1 Bridge program, the first time Medicare has paid for obesity medications. The pilot runs through December 31, 2027 and covers Zepbound KwikPens, Wegovy pills and injections, and Foundayo. You must be enrolled in a Part D plan, meet the program's clinical criteria, and have your prescriber submit a prior authorization; the $50 copays do not count toward your Part D deductible. CMS publishes the program's enrollee criteria in detail on Medicare.gov. Whether you meet the clinical requirements is determined through the prior authorization process with your physician, and traditional Part D plans still exclude weight loss drugs outside this program.

More questions, answered

Related questions